Skip to main content

Table 1 Characteristics of enrolled subjects

From: Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients

Variables COPD (n = 57) Asthma (n = 89) P-values
Male, n (%) 43 (75.4) 43 (48.3) 0.001
Median (IQR) age, years 73 (66–77) 59 (51–69) < 0.0001
Median (IQR) BMI, kg/m2 27 (24.0–30.8) 26 (23.0–29.4) 0.09
Median (IQR) pack-year 38 (23–50) 0 (0–10) < 0.0001
GOLD stages, %
 1 33.3   
 2 56.1
 3 10.5
GOLD categories, %
 A 35.2   
 B 44.4
 C 9.3
 D 11.1
GINA steps, %
 1   3.8  
 2 11.4
 3 32.9
 4 40.5
 5 11.4
Median (IQR) FEV1, L 1.7 (1.3–2.2) 2.1 (1.8–3.1) 0.0001
Mean (SD) FEV1, % 71.7 (19.1) 88.6 (23.5) < 0.0001
Median (IQR) FVC, L 3.3 (2.6–3.8) 3.3 (2.6–4.1) 0.82
Mean (SD) FVC, % 98.0 (17.2) 100.8 (20.7) 0.39
Mean (SD) FEV1/FVC 55.9 (10.1) 69.6 (10.4) < 0.0001
Median (IQR) blood leucocytes, mmc 6.7 (5.9–8.1) 6.9 (5.7–8.0) 0.96
Mean (SD) blood neutrophils, % 57.5 (9.2) 53.6 (9.1) 0.01
Mean (SD) blood lymphocytes, % 28.5 (8.9) 32.5 (8.1) 0.006
Median (IQR) blood eosinophils, % 2.9 (1.8–3.9) 3.6 (2.0–6.0) 0.047
Median (IQR) blood eosinophils, 210.6 (117.8–307.8) 238.5 (135.7–427.0) 0.12
Median (IQR) PCR (n = 28 VS. 21) 0.3 (0.1–0.7) 0.3 (0.1–0.6) 0.93
Median (IQR) sputum cells, × 104/ml 204.5 (81.2–330.0) 125.5 (61–320) 0.23
Median (IQR) sputum macrophages, % 16.1 (9.7–27.0) 18.9 (8.8–31.1) 0.35
Median (IQR) sputum neutrophils, % 74.8 (60.4–82.2) 58.4 (25.1–74.4) < 0.0001
Median (IQR) sputum eosinophils, % 1.7 (0.8–3.2) 4.3 (1.0–24.3) 0.002
Median (IQR) sputum lymphocytes % 0.8 (0.6–1.7) 1.4 (0.7–2.0) 0.12
Median (IQR) sputum epithelial cells % 3.3 (1.4–6.4) 4.0 (1.7–8.2) 0.34
Inhaled corticosteroids (ICS), % 10.7 85.9 < 0.0001
Exacerbations previous year, yes/no n (%) 23 (40.4) 34 (38.2) 0.88
Median (IQR) number of exacerbations during the previous year 0 (0–1) 0 (0–1) 0.86
  1. OSAS Obstructive sleep apnoea syndrome, IQR interquartile range, SD standard deviation, PCR C reactive protein, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroids